Vollständiger Abstract
Worum geht es in dieser Arbeit?
Resistance-associated mutations (RAMs) limit treatment options for HIV. We evaluated virologic outcomes in people with HIV harboring RAMs who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a real-world cohort during 4 years of follow-up. Virologic suppression was sustained across RAM subgroups, including M184V/I with additional nucleoside reverse transcriptase inhibitor (NRTI)-RAMs. Stratification by genotypic susceptibility score (GSS) suggests robust effectiveness. B/F/TAF demonstrates durable long-term suppression in different resistance profiles, supporting its use in this population.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Cinthia S. Lamaizón, Diego Cecchini, Martin Brizuela, Gastón Copertari, Brenda Bacelar, Macarena Roel, Edgardo Bottaro, Lidia I. Cassetti
- Quelle
- AIDS
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0269-9370, 1473-5571
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Cinthia S. Lamaizón, Diego Cecchini, Martin Brizuela, Gastón Copertari, Brenda Bacelar, Macarena Roel, Edgardo Bottaro, Lidia I. Cassetti (2026). Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations. AIDS. https://doi.org/10.1097/qad.0000000000004553